Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

Vertex Pharmaceuticals achieved compound earnings per share (EPS) growth of 1.5% per year. We do note that extraordinary items have impacted its earnings history. This EPS growth is lower than the ...

Below is a chart showing the trailing twelve month trading history for Vertex Pharmaceuticals, Inc., and highlighting in green where the $395.00 strike is located relative to that history ...

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of ... markets for Vertex's new treatment could be those with a prior history of addiction and obese patients where respiratory depression ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller ... It's a milestone after a long history of unsuccessful efforts to develop painkillers without the ...